Article
Identification of cross-stage, cross-species malaria CD8+ T cell antigens.
Nature - 1 Jul 2026
Barbosa Camila R R, de Lacerda Luna B, Bettencourt Paulo J G, Morrow David, Pereira Dhelio B, Aleshnick Maya, Mitchell Julie L, Poulton Nicholas C, Gomes Cristopher, Cordeiro Lídia P B, Doumbia Kadia, Ntalla Christina, Arama Charles, Zhao Zezhou, Maia Guilherme C, Almeida Gregório G, Schrimpf Marie Rose, Hart Thalia F, Haumpy Derek, Medeiros-Rodrigues Beatriz C, Costa Camila M, Nicastri Annalisa, Gilbride Roxanne M, Schell John B, Kirtley Payton, Antonelli Lis R V, Gaiha Gaurav D, Hansen Scott G, Lieberman Judy, Gazzinelli Ricardo T, Niangaly Moussa, Woodford John, Goldberg Joel, Früh Klaus, Portugal Silvia, Duffy Patrick E, Ternette Nicola, Wilder Brandon, Hill Adrian V S, Junqueira Caroline
Abstract excerpt
A major limitation on the development of a malaria vaccine is the lack of validated T cell epitope targets. Plasmodium falciparum is the most prevalent malaria parasite affecting humans in Africa, whereas Plasmodium vivax is more widespread and is the main species that causes malaria in the Americas and Asia1. P. vivax exclusively infects peripheral-blood reticulocytes, which retain RNA and the capacity for host...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.